medcelerator · clinician one-pager
A New Copper Treatment for Children with Menkes Disease
Zycubo (copper histidinate) — subcutaneous copper replacement for Menkes disease in pediatric patients
FDA Approved · United States · September 11, 2026
Condition: Menkes Disease
Who this is for
This is for families of children with Menkes disease who may be candidates for labelled US Zycubo subcutaneous copper replacement — especially when treatment can start early after birth. It explains the first FDA-labelled Menkes therapy, the age-based once- or twice-daily injection schedule, overall-survival results versus external controls, copper-toxicity lab monitoring, caregiver injection training, and how to talk with a metabolic genetics clinician — without treating an EMA orphan designation, a DIY compounded copper product, or completed trial records as open enrolment. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211241s000lbl.pdf
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/zycubo-copper-histidinate